These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 7961287)

  • 41. [New findings in the diagnosis of minimal residual disease in acute leukemia with emphasis on flow cytometry].
    Vosková D; Váleková L; Kubisz P
    Vnitr Lek; 1997 May; 43(5):332-6. PubMed ID: 9601859
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Flow cytometry in clinical pathology.
    Virgo PF; Gibbs GJ
    Ann Clin Biochem; 2012 Jan; 49(Pt 1):17-28. PubMed ID: 22028426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How to optimize multiparameter flow cytometry for leukaemia/lymphoma diagnosis.
    Paietta E
    Best Pract Res Clin Haematol; 2003 Dec; 16(4):671-83. PubMed ID: 14592650
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
    Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
    Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Flow Cytometry in Pediatric Malignancies.
    Handoo A; Dadu T
    Indian Pediatr; 2018 Jan; 55(1):55-62. PubMed ID: 29396936
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules.
    Wilkerson MJ; Dolce K; Koopman T; Shuman W; Chun R; Garrett L; Barber L; Avery A
    Vet Immunol Immunopathol; 2005 Jul; 106(3-4):179-96. PubMed ID: 15963817
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunophenotyping of congenital leukemia.
    McCoy JP; Overton WR
    Cytometry; 1995 Jun; 22(2):85-8. PubMed ID: 7587752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [10 years' experiences with flow cytometric immunological phenotyping in malignant hematologic diseases].
    Kristensen JS; Hokland P
    Ugeskr Laeger; 1996 Oct; 158(43):6098-102. PubMed ID: 8928296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow.
    Ahmad E; Kingma DW; Jaffe ES; Schrager JA; Janik J; Wilson W; Stetler-Stevenson M
    Cytometry B Clin Cytom; 2005 Sep; 67(1):6-12. PubMed ID: 15973700
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies.
    Bromberg JE; Breems DA; Kraan J; Bikker G; van der Holt B; Smitt PS; van den Bent MJ; van't Veer M; Gratama JW
    Neurology; 2007 May; 68(20):1674-9. PubMed ID: 17502548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytologic diagnosis of leukemia and lymphoma. Values and limitations.
    Katz RL
    Clin Lab Med; 1991 Jun; 11(2):469-99. PubMed ID: 1873967
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias.
    Kern W; Kohlmann A; Schoch C; Schnittger S; Haferlach T
    Cancer; 2006 Nov; 107(10):2401-7. PubMed ID: 17041886
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Towards standardization in immunophenotyping hematological malignancies. How can we improve the reproducibility and comparability of flow cytometric results? Working Group on Leukemia Immunophenotyping.
    Lanza F
    Eur J Histochem; 1996; 40 Suppl 1():7-14. PubMed ID: 8839695
    [No Abstract]   [Full Text] [Related]  

  • 54. Immunophenotyping leukemias: the new force in hematology.
    Sullivan JG; Wiggers TB
    Clin Lab Sci; 2000; 13(2):117-22. PubMed ID: 11066450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia.
    Wood BL; Arroz M; Barnett D; DiGiuseppe J; Greig B; Kussick SJ; Oldaker T; Shenkin M; Stone E; Wallace P
    Cytometry B Clin Cytom; 2007; 72 Suppl 1():S14-22. PubMed ID: 17803189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of the new Beckman Coulter Cytomics FC 500 5-color flow cytometer on a regional flow cytometry clinical laboratory service.
    Luider J; Cyfra M; Johnson P; Auer I
    Lab Hematol; 2004; 10(2):102-8. PubMed ID: 15224766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD56+/CD4+ lymphomas and leukemias are morphologically, immunophenotypically, cytogenetically, and clinically diverse.
    Rakozy CK; Mohamed AN; Vo TD; Khatib G; Long PM; Eilender D; Palutke M
    Am J Clin Pathol; 2001 Aug; 116(2):168-76. PubMed ID: 11488062
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monitoring of minimal residual disease in leukemia, advantages and pitfalls.
    Cazzaniga G; Gaipa G; Rossi V; Biondi A
    Ann Med; 2006; 38(7):512-21. PubMed ID: 17101542
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Differential malignant lymphoproliferative syndrome (LPS) diagnosis with flow cytometry: a study of 100 patients].
    Cardile N; Sabo G; Butsch P; Brengarth E; Viollier AF; Knecht H
    Praxis (Bern 1994); 2000 Jan; 89(4):143-9. PubMed ID: 10686807
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute lymphoblastic leukemia: diagnosis and detection of minimal residual disease following therapy.
    Digiuseppe JA
    Clin Lab Med; 2007 Sep; 27(3):533-49, vi. PubMed ID: 17658406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.